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Abstract
Hereditary hemochromatosis, an iron overload disease associated with excessive intestinal iron absorption, is commonly
caused by loss of HFE gene function. Both iron and manganese absorption are regulated by iron status, but the
relationships between the transport pathways of these metals and how they are affected by HFE-associated
hemochromatosis remain poorly understood. Loss of HFE function is known to alter the intestinal expression of DMT1
(divalent metal transporter-1) and Fpn (ferroportin), transporters that have been implicated in absorption of both iron and
manganese. Although the influence of HFE deficiency on dietary iron absorption has been characterized, potential effects
on manganese metabolism have yet to be explored. To investigate the role of HFE in manganese absorption, we
characterized the uptake and distribution of the metal in Hfe
2/2 knockout mice after intravenous, intragastric, and
intranasal administration of
54Mn. These values were compared to intravenous and intragastric administration of
59Fe.
Intestinal absorption of
59Fe was increased and clearance of injected
59Fe was also increased in Hfe
2/2 mice compared to
controls. Hfe
2/2 mice displayed greater intestinal absorption of
54Mn compared to wild-type Hfe
+/+ control mice. After
intravenous injection, the distribution of
59Fe to heart and liver was greater in Hfe
2/2 mice but no remarkable differences
were observed for
54Mn. Although olfactory absorption of
54Mn into blood was unchanged in Hfe
2/2 mice, higher levels of
intranasally-instilled
54Mn were associated with Hfe
2/2 brain compared to controls. These results show that manganese
transport and metabolism can be modified by HFE deficiency.
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Introduction
High levels of manganese impair neurobehavior in both humans
and animal models [1–5]. Fortunately, manganese loading due to
ingestion is relatively rare since hepatic first-pass elimination of the
metal provides a protective mechanism against toxicity [6].
However, intake of airborne manganese bypasses the biliary
excretion route and inhaled manganese is efficiently transported
into the body including the brain through the nasal epithelium [7–
9]. High levels of airborne manganese are common in occupa-
tional settings of mining, manganese ore processing, dry battery
manufacture and organochemical fungicide use [10,11], raising
concerns about public and occupational health problems. Recent
work by Haynes et al. [12] determined hair and blood manganese
levels in residents living near Marietta OH and a ferromanganese
refinery that is a major US airborne emission source. The
relationship between these biomarkers and ambient air levels of
manganese became significant when iron metabolism genes,
including HFE (hyperferremia) alleles, were incorporated in their
models [12]. Our group recently uncovered a relationship between
HFE status and manganese metabolism by demonstrating that
Hfe
2/2 knockout mice have reduced levels of blood manganese
[13]. This observation validated an epidemiological study of
demonstrating human carriers of disease-associated HFE(C282Y)
or HFE(H63D) alleles also have lower blood manganese [13].
The HFE(C282Y) and HFE(H63D) variants in the iron
regulatory HFE gene are the leading cause of adult onset
hereditary hemochromatosis (HH), one of the most common
genetic diseases in the North American Caucasian population.
C282Y and H63D have prevalence in North American popula-
tions of 7–17% and 10–32%, respectively [14]. HFE-associated
HH is the most common Mendelian inherited trait of northern
Europeans, with a prevalence of 1:200 to 1:500 [15,16]. Defects in
the HFE gene promote increased intestinal iron absorption and
progressive tissue deposition of the metal resulting in liver damage
and disease, congestive heart failure, and premature death. Mice
with either the orthologous mutations or null allele display the
same iron-loading HH phenotype observed in humans [17].
The effects of iron loading on manganese in vivo have been well
established [13,18,19]. Recent molecular studies have documented
a role for divalent metal transporter-1 (DMT1) in manganese
uptake [20–23]. DMT1 functions in dietary iron absorption across
the apical surface of the intestinal mucosa [24,25] and transports
iron from endocytosed transferrin to enable heme synthesis by
erythroid cells [26]. Because impaired DMT1 function also results
in reduced manganese transport [20], the transporter appears to
play an important physiological role in the metabolism of this
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exporter ferroportin (Fpn) [27,28] also transports manganese
[29,30]. There is strong evidence in the literature that HFE
deficiency alters levels of both transporters [31–33]. However,
while the influence of HFE deficiency on dietary iron absorption
has been characterized, its potential effects on manganese
metabolism have not been explored. Therefore, we undertook
this investigation to characterize the uptake and distribution of the
metal in Hfe
2/2 knockout mice after intravenous, intragastric, and
intranasal administration of
54Mn.
Results and Discussion
Iron loading characteristics of HFE deficiency
Several studies have characterized the iron-loading phenotype
of Hfe knockout (Hfe
2/2) mice [17,34–36]. In our hands, Hfe
2/2
mice also displayed an age-dependent increase in liver non-heme
iron levels, which were elevated as early as 4 weeks of age
(Figure 1A; P,0.001; n=9–14 per group). These data are
consistent with findings by other investigators [37,38]. To
characterize the effect of dietary iron on the iron-loading
phenotype, weanling mice were fed iron deficient (5 mg/kg),
control (50 mg/kg) or high iron (20,000 mg/kg) diet. Non-heme
iron levels in both liver and serum increased in a manner
corresponding to dietary iron content regardless of genotype
(Figure 1B and C). Liver non-heme iron levels were greater in
Hfe
2/2 mice than in wild-type control (Hfe
+/+) mice fed control
diet (Figure 1B; P,0.001; n=8–12 per group), while the other two
diets did not show significant differences between the two strains.
Similarly, Hfe
2/2 mice fed the control diet displayed significantly
higher serum iron concentrations compared with Hfe
+/+ mice
(Figure 1C; P,0.001; n=8–12 per group). It is notable that this
pattern was also observed in mice fed iron-deficient diet and high
iron diet (Figure 1C; P,0.001 and P=0.042, respectively; n=6–8
per group). In contrast to results reported by others [39,40],
Hfe
2/2 and Hfe
+/+ mice fed a high iron diet had similar liver non-
heme iron levels, but this difference could be due to strain
variation (129/SvJ vs C57BL/6) or the different duration of
dietary iron (2–6 weeks) [39–41]. To control for the influence of
body iron status on the metal uptake studies described below, both
Hfe
2/2 and Hfe
+/+ mice were fed the control diet containing
50 mg/kg iron for 5 weeks after the time of weaning.
HFE deficiency enhances intestinal uptake of
59Fe and
clearance of
59Fe from circulation
To examine the influence of HFE on intestinal iron uptake,
59Fe
was administered to Hfe
2/2 and Hfe
+/+ mice by intragastric
gavage. Iron was reduced to the ferrous form using freshly
dissolved ascorbate immediately prior to instillation. Blood levels
of
59Fe were determined 4 h after administration (Figure 2A).
Hfe
2/2 mice accumulated a greater amount of iron in blood over
the 4-hour period compared to Hfe
+/+ wild-type controls
(P=0.034; n=4–5 per group). This observation is consistent with
the hyperabsorption of iron from the gut of Hfe
2/2 mice
[36,37,42]. However, we considered the additional possibility that
increased appearance of
59Fe in the blood after gavage could be
due to decreased clearance. Thus, we also characterized blood
clearance following intravenous injection of
59Fe (Figure 2B). Four
hours after intravenous injection, the amount of
59Fe in the blood
was less in Hfe
2/2 compared to Hfe
+/+ mice (P=0.008; n=5 per
group), indicating that loss of HFE function contributes to
enhanced uptake of iron by peripheral tissues and/or excretion
from the body. The accelerated blood clearance promoted by
HFE deficiency could be explained by an increased fraction of
non-transferrin-bound iron, which displays faster clearance
kinetics than transferrin-bound iron [43]. Trinder et al [39] have
shown that
59FeTf uptake is similar in Hfe knockout and wild-type
mice. Despite more rapid clearance of injected
59Fe, blood
59Fe
levels after gavage were still greater in Hfe
2/2 mice (Figure 2A).
These combined data suggest an even larger extent of ‘‘intrinsic’’
intestinal uptake (bioavailability) of iron in the absence of HFE.
The calculated bioavailability after correcting for blood clearance
of iron during absorption over the 4 hour time period was 3-fold
greater in Hfe
2/2 mice compared with Hfe
+/+ mice (Table 1,
Figure 1. HFE deficiency and iron-loading. Weanling mice were
fed facility chow (220 mg/kg iron), euthanized with isoflurane overdose
at the indicated ages. Liver non-heme iron levels (A) were determined
for Hfe
+/+ (empty bar) and Hfe
2/2 (closed bar) mice. Data were
presented as means 6 SEM (n=9–14 per group). Weanling mice were
fed iron-deficient (5 mg/kg iron), control (50 mg/kg), or high iron diet
(20,000 mg/kg). After 5 weeks, mice were euthanized with isoflurane
overdose, and liver (B) and serum non-heme iron (C) levels were
determined for Hfe
+/+ and Hfe
2/2 mice. Data were presented as means
6 SEM (n=6–12 per group). * P,0.05 between Hfe
+/+ and Hfe
2/2 mice
determined by two-way ANOVA followed by Tukey’s post-hoc
comparison.
doi:10.1371/journal.pone.0064944.g001
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regulation of the intestinal iron transporters DMT1 and/or Fpn
has been reported in HFE deficiency [31–33] and would
contribute to the observed effects as discussed below.
HFE deficiency promotes delivery of
59Fe to liver and
heart
To further examine the influence of HFE on blood clearance of
iron, mice were euthanized 4 h after the injected dose and
radioactivity in tissue samples was measured to determine the
degree of
59Fe uptake (Figure 3A). Hfe
2/2 mice exhibited a 1.4-
fold increase in
59Fe uptake in the liver compared with Hfe
+/+ mice
(P=0.003; n=5 per group). Moreover,
59Fe in the heart after
intravenous injection was 0.5-fold greater in Hfe
2/2 mice than in
Hfe
+/+ mice (P=0.033; n=5 per group). Thus, loss of HFE
function results in increased tissue uptake to the liver and heart.
These observations are of interest since the major causes of death
related to iron overload hemochromatosis are liver toxicity and
cardiomyopathy [44]. Previous studies by Ajioka et al. [37]
reported increased liver distribution of
59Fe after gavage. The idea
that loss of HFE function leads to hepatic iron loading is consistent
with other studies [17,34–36]. Turoczi et al. [45] investigated iron
loading of cardiac tissue in Hfe
2/2 mice and showed increased
iron deposition and reactive oxygen species (ROS). These data
support the notion that preferential uptake of iron into these two
major organs is associated with metal-related oxidative stress and
tissue damage. While the presence of increased non-transferrin
bound iron could promote these effects [43], it is possible that
differential expression of certain iron transporters contributes to
the specific uptake of
59Fe; for example, Zip14 in liver [46]. In our
experiments, the total radioactivity remaining in the carcass was
similar in the two groups (data not shown), suggesting that
excretion of iron cannot account for increased blood clearance in
HFE deficiency. We conclude that the deposition of iron into key
target tissues, particularly the liver, is promoted by HFE
deficiency.
Figure 2. Effect of HFE deficiency on absorption of
59Fe and
54Mn after intragastric gavage and intravenous injection. Blood
levels of
59Fe as nCi/g blood were characterized 4 h post-dose of
59FeCl3 (200 mCi/kg body weight) to mice by intragastric gavage (A) and
intravenous injection (B). Empty and closed bars represent Hfe
+/+ and
Hfe
2/2 mice, respectively. Data were presented as mean 6 SEM (n=4–5
per group). Blood levels of
54Mn as nCi/g blood were characterized 1 h
post-dose of
54MnCl2 (200 mCi/kg body weight) to mice by intragastric
gavage (A) and intravenous injection (B). Data were presented as
means 6 SEM (n=4–10 per group). * P,0.05 between Hfe
+/+ and
Hfe
2/2 mice determined by two-sample t-test.
doi:10.1371/journal.pone.0064944.g002
Table 1. Intestinal bioavailability of iron and manganese.
Wild-type (%) HFE-deficient (%)
59Fe 19.0 6 4.2 81.1* 6 7.3
54Mn 2.3 6 0.2 3.6* 6 0.4
Mice were euthanized after intravenous injection or intragastric gavage of the
indicated isotopes (200 mCi/kg body weight). Blood and tissues were collected
4-hour after
59Fe dose or 1-hour after
54Mn dose. Blood concentration after
intragastric gavage was divided by the concentration determined after
intravenous injection to estimate time-variant intestinal bioavailability of each
metal. Data are presented as the mean 6 SEM.
*P,0.05 between Hfe
+/+ and Hfe
2/2 mice determined by two-sample t-test.
doi:10.1371/journal.pone.0064944.t001
Figure 3. Uptake of injected
59Fe and
54Mn to brain, heart and
liver. Levels of
59Fe in brain, heart and liver (as nCi/g tissue) were
characterized 4 h post-dose of
59FeCl3 (200 mCi/kg body weight) to
mice by intravenous injection (A). Levels of
54Mn in brain, heart and
liver (as nCi/g tissue) were characterized 1 h post-dose of
54MnCl2
(200 mCi/kg body weight) to mice by intravenous injection (B). Empty
and closed bars represent Hfe
+/+ and Hfe
2/2 mice, respectively. Data
were presented as mean 6 SEM (n=4–5 per group for
59Fe and n=7–8
per group for
54Mn). * P,0.05 between Hfe
+/+ and Hfe
2/2 mice
determined by two-sample t-test.
doi:10.1371/journal.pone.0064944.g003
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uptake
To determine the role of HFE in manganese absorption, we also
measured the amount of
54Mn in blood after intragastric gavage or
intravenous injection of the radioisotope (Figure 2). Hfe
2/2 mice
displayed higher blood
54Mn levels than Hfe
+/+ mice 1 h after
gavage (Figure 2A; P=0.036; n=4 per group), indicating that like
iron, intestinal absorption of manganese is enhanced by HFE
deficiency (Table 1). Unlike iron, there was no difference in blood
clearance of
54Mn administered by injection (Figure 2B; P=0.488;
n=7–8 per group). Tissue distribution of
54Mn was similar
between Hfe
2/2 and Hfe
+/+ mice with no difference in uptake by
heart or liver (Figure 3B). The observations that manganese
clearance from circulation is not altered despite high serum iron
and accelerated iron clearance in HFE deficiency (Figure 2B) is
interesting. It is possible there are potential differences in the
kinetics of manganese clearance from circulation by both Hfe
+/+
and Hfe
2/2 mice earlier than the 1 h time point of our tracer
study. We chose 1 h for
54Mn sampling since manganese
absorption reached a plateau level in the brain 1 h following
intranasal instillation of
54Mn and we therefore monitored blood
clearance over the same time frame (see below). Further study is
necessary to more fully characterize clearance of manganese from
circulation in Hfe
2/2 mice, including the effects of continuous
administration and chronic inhalation of manganese [9,47,48].
Although the kinetics of manganese clearance after intravenous
injection need to be better defined, the fact that
54Mn did not
accumulate in liver and heart of Hfe
2/2 mice suggests the removal
of manganese from the vasculature may follow pathways that are
different from iron.
Olfactory manganese uptake into the brain is enhanced
by HFE deficiency
Absorption of airborne manganese is an increasing concern due
to neurotoxicity of the metal [49]. To study the influence of HFE
deficiency on olfactory absorption, uptake of
54MnCl2 was
examined in Hfe
2/2 and Hfe
+/+ mice after intranasal instillation.
Preliminary studies demonstrated that
54Mn absorption to the
brain was maximal 1 h post-instillation. Levels of
54Mn in Hfe
2/2
and Hfe
+/+ in the blood 1 h after instillation did not differ
(Figure 4A; P=0.090; n=7–8 per group). It is interesting to note
that the overall amount of isotope absorbed from the nasal cavity
into the blood was much higher than the amount taken up after
intragastric gavage, regardless of genotype (Figure 2A). These data
demonstrate the greater efficiency of systemic manganese uptake
via the olfactory pathway compared to the oral route [7–9],
Figure 4. Effect of HFE deficiency on manganese uptake after
intranasal instillation. One hour after intranasal instillation of
54MnCl2 (200 mCi/kg), blood (A) and brain (B) samples were weighed
and radioactivity was measured to calculate isotope level as nCi/g
blood or brain. Empty and closed bars represent Hfe
+/+ and Hfe
2/2
mice, respectively. Data were presented as means 6 SEM (n=7–8 per
group). * P,0.05 between Hfe
+/+ and Hfe
2/2 mice determined by two-
sample t-test.
doi:10.1371/journal.pone.0064944.g004
Figure 5. Levels of transporters and metals in olfactory bulbs
of wild-type and HFE knockout mice. Weanling mice were fed
control diet and euthanized to collect olfactory bulbs. Levels of DMT1
(A) and Fpn (B) were determined by western blot. Data were presented
as means 6 SEM (n=6 per group). Olfactory bulbs from 3 male and 5
female Hfe
+/+ mice and 4 male and 4 female Hfe
2/2 mice were pooled
and determined for iron and manganese levels by ICP-MS (C). Data
were presented as means.
doi:10.1371/journal.pone.0064944.g005
Manganese Transport in HFE Deficiency
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intoxication, especially in occupational settings [5,6]. Moreover,
our data show that uptake to the brain after intranasal instillation
was increased in Hfe
2/2 mice compared with Hfe
+/+ mice
(Figure 4B; P=0.028; n=7–8 per group). This effect appears to
be specific for brain uptake by the olfactory pathway since no
differences were detected between the groups after intragastric
gavage or intravenous injection (Figure 2 and 3B). Notably, the
uptake of manganese (Figure 3B) and iron (Figure 3A) across the
blood-brain barrier in HFE deficiency is unaffected. Combined,
these observations suggest different mechanism(s) of metal uptake
between olfactory and vascular transport to the brain. The latter
may be primarily mediated by transferrin. Nonetheless, the
observed increase in uptake to the brain of Hfe
2/2 mice suggests
that individuals with HFE-associated hemochromatosis may be
more vulnerable to neurotoxicity of inhaled manganese.
DMT1 and Fpn expression in olfactory bulb
It is known that increased absorption of iron across the intestinal
mucosa is promoted by up-regulation of DMT1 and Fpn
[24,28,50]. Both transporters are post-transcriptionally regulated
by iron-responsive elements [51,52]. In the case of HFE
deficiency, post-translational modification also is imparted by the
iron regulatory hormone hepcidin [53,54], which is inappropri-
ately down-regulated to enhance Fpn levels [55,56]. We have
previously found that systemic iron deficiency induces DMT1 up-
regulation in the olfactory epithelium [20] and olfactory bulbs
[57], an effect that is associated with increased olfactory transport
of manganese to the brain [20,21]. Therefore, we compared
DMT1 and ferroportin levels in the olfactory bulbs from Hfe
2/2
with Hfe
+/+ mice (Figure 5A and B). Despite the iron overload
status of Hfe
2/2 mice (Figure 1), levels of both transporters were
similar in the two groups. However, ICP-MS analysis of the metal
content of the olfactory bulbs from wild-type and knockout mice
showed no differences that would otherwise promote changes in
the expression pattern of the transporters at the tissue level
(Figure 5C). Levels of iron were 50-fold greater than manganese.
These results indicate that there could be other factors indepen-
dent of DMT1 or Fpn involved in manganese transport across
nasal cavity into brain that are affected by the loss of HFE
function. For example, local regulation of hepcidin may play an
important role in metal uptake in the brain [58]. Other transport
pathways could also influence brain uptake of airborne manga-
nese, including newly emerging roles for SLC30A10 transporters
[59,60] and manganese binding proteins like calprotectin [61].
Further work is necessary to define the manganese pathways
affected in Hfe
2/2 mice and the functional consequences due to
the increased uptake of manganese from the nasal cavity to the
brain.
Conclusions
N HFE-deficient mice displayed elevated intestinal absorption of
both iron and manganese.
N HFE-deficient mice had greater uptake of intravenously
injected
59Fe by liver and heart, while uptake of
54Mn to
these tissues was unaffected.
N Regardless of genotype, greater levels of
54Mn were present in
the blood after intranasal instillation compared to administra-
tion by intragastric gavage.
N HFE-deficient mice had greater uptake of intranasally-instilled
54Mn into the brain.
N DMT1 and Fpn are expressed in olfactory bulb, however,
levels of both transporters were similar in HFE-deficient and
wild-type mice.
N HFE deficiency was not associated with altered levels of iron or
manganese in olfactory bulbs; levels of iron were 50-fold
greater than manganese.
N Loss of HFE increases uptake of manganese to the brain by the
olfactory pathway, suggesting individuals with HFE-associated
hemochromatosis may be at greater risk for inhalation
exposures.
Materials and Methods
Ethics statement
This study was performed in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Harvard Medical Area Animal Care
and Use Committee (Animal Experimentation Protocol AEP
#04545 and #04692).
Animal care and procedures
HFE-deficient (Hfe
2/2) mice and wild-type control (Hfe
+/+)
mice were kindly provided by Dr. Nancy Andrews (Duke
University, NC). All mice used for these studies were on the
129S6/SvEvTac background. Weanling mice were fed a diet
containing 50 mg iron/kg (as ferric citrate, TD07800, Harlan
Teklad) for 5 weeks. For experiments testing the effect of dietary
iron, groups of knockout and wild-type mice were also placed on
iron-deficient diet (5 mg iron/kg diet; TD99397), or iron-overload
diet (20,000 mg/kg; as carbonyl iron, TD08714). Mice were
euthanized under isoflurane inhalation (5%) to obtain serum and
liver, and non-heme iron concentrations in these tissues were
determined by spectrophotometric methods [62,63]. All experi-
ments were carried out between 12–3 p.m. to avoid circadian
effects on iron metabolism. No obvious gender differences were
noted in the transport studies described below.
To characterize gastrointestinal absorption of iron, 8-week-old
mice were fasted for 4 hours, anesthetized with up to 2%
vaporized isoflurane, and administered
59FeCl3 (200 mCi/kg body
weight) or
54MnCl2 (200 mCi/kg body weight) by intragastric
gavage using a 20 gauge 1.5-inch gavage needle.
59Fe was diluted
in Tris-buffered saline containing ascorbic acid (10 mM) at
1.5 mL/kg immediately prior to administration;
54Mn was diluted
in phosphate-buffered saline (PBS). Mice were euthanized by
isoflurane overdose 4 h post-gavage to collect blood via the inferior
vena cava and tissues were dissected. Radioactivity was deter-
mined using a WIZARD 1410 gamma counter (Perkin Elmer).
Data were analyzed and expressed as nCi/g tissue. Since the blood
levels of
59Fe represent the amount absorbed from the gut as well
as the amount cleared from the circulation, similar cohorts of mice
were intravenously injected with the same dose of
59Fe or
54Mn via
the tail vein to account for the contribution of clearance to the
blood level. To study intranasal absorption,
54Mn was instilled into
the right nostril at 0.02 mL/kg using a thin polyurethane catheter
(mouse jugular catheter; Alzet, Cupertino, CA). Since a pilot study
showed that a plateau level of
54Mn was achieved in the brain one
hour post-instillation, intravenous, intragastric, or intranasal
absorption were each studied 1 h post-administration.
Western blots
Olfactory bulbs from male Hfe
+/+ and Hfe
2/2 mice were
homogenized in 10 mM Tris, pH 7.4, 150 mM NaCl, 1.0 mM
Manganese Transport in HFE Deficiency
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late containing protease inhibitors (Complete Mini, Roche).
Aliquots 30 mg (DMT1) or 40 mg (ferroportin) were prepared in
sample buffer without boiling and electrophoresed on 10% gels.
After transfer to nitrocellulose membranes, blots were blocked
with 5% non-fat milk and immunoblotted using rabbit anti-DMT1
(all four isoforms) antibody (1:1,000; a kind gift from Dr. Jerry
Kaplan, The University of Utah, Salt Lake City, UT) or rabbit
anti-ferroportin antibody (1:500; Alpha Diagnostics). Blots were
probed with mouse anti-actin (MP Biomedicals) as a loading
control. Secondary antibodies were donkey anti-rabbit IRDye800
(DMT1; LI-COR), donkey anti-rabbit HRP (ferroportin; GE) or
donkey anti-mouse IRDye680 (Actin; LI-COR). Immunoreactivity
was detected using an Odyssey Infrared Imaging System (DMT1
and actin; LI-COR) or ECL (ferroportin; West Pico, Thermo
Scientific). Relative intensities of protein bands were determined
using Odyssey (version 2.1; LI-COR) or Image J software (version
1.43; NIH).
ICP-MS
Olfactory bulbs from 3 male and 5 female Hfe
+/+ mice and 4
male and 4 female Hfe
2/2 mice were pooled and analyzed for iron
and manganese levels by ICP-MS (Trace Element Analysis
Laboratory, Dept. of Earth Sciences, Dartmouth College, Han-
over, NH).
Statistical analyses
Values reported were expressed as means 6 SEM. For multi-
group comparison (gene and diet effect), two-way ANOVA test
followed by Tukey’s post-hoc comparison was used. Two-sample t-
test was employed to compare the parameters between Hfe
2/2
and Hfe
+/+ mice using Systat 13 (Systat). Differences were
considered significant at P,0.05.
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